Effect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian Syndrome

Haemoglobin A1c in percentage.

We will conduct a subgroup analysis with participants who have an abnormal HbA1c (more than 5.9%) at baseline.

Fasting Blood Glucose (FBG), in mmol/L

We will conduct a subgroup analysis with participants who have an abnormal FBG (more than 6.22 mmol/L) at baseline.

Serum insulin level, μU/mL.

We will conduct a subgroup analysis with participants who have an abnormal insulin (more than 24.8 μU/mL) at baseline.

Homeostatic Model Assessment of Insulin Resistance, no unit.

We will conduct a subgroup analysis with participants who had abnormal HOMA-IR (more than 2.0) at baseline.

Luteinising hormone, in IU/L.

We will conduct a subgroup analysis with participants who had abnormal LH (more than 11.6) at baseline.

Ratio of luteinising hormone on follicle-stimulating hormone.

We will conduct a subgroup analysis with participants who had abnormal LH/FSH (more than 2.0) at baseline.

Progesterone level, ng/mL.

We will conduct a subgroup analysis with participants who had abnormal progesterone (more than 2.1) at baseline.

Testosterone levels, ng/mL

We will conduct a subgroup analysis with participants who had abnormal testosterone (more than 0.55 ng/mL) at baseline.

Weight measured by a weight scale, in kg

We will conduct two subgroup analyses with participants who are overweight (more than 25 kg/m2) and obese (more than 30 kg/m2) at baseline, respectively.

Body Mass Index, calculated based on the weight and height, in kg/m2.

We will conduct two subgroup analyses with participants who are overweight (more than 25 kg/m2) and obese (more than 30 kg/m2) at baseline, respectively.

Waist size measured with a measuring scale, in cm.

We will conduct a subgroup analyses with participants who had an excessive waist circumference (more than 80 cm) at baseline.

Buttocks size measured with a measuring scale, in cm.

We will conduct a subgroup analyses with participants who had an excessive buttocks circumference (more than 93 cm) at baseline.

Thigh size measured with a measuring scale, in cm.

Systolic blood pressure, in mmHg.

We will conduct a subgroup analyses with participants who had an excessive SBP (more than 120 mmHg) at baseline.

Diastolic blood pressure, in mmHg.

We will conduct a subgroup analyses with participants who had an excessive DBP (more than 90 mmHg) at baseline.

Total cholesterol, in mmol/L.

We will conduct a subgroup analyses with participants who had an excessive total cholesterol (more than 5.6 mmol/L) at baseline.

Triglycerides, in mmol/L.

We will conduct a subgroup analyses with participants who had excessive triglycerides (more than 2.3 mmol/L) at baseline.

Low density lipoprotein, in mmol/L.

We will conduct a subgroup analyses with participants who had an excessive waist circumference (more than 4.11 mmol/L) at baseline.

High density lipoprotein, in mmol/L.

We will conduct a subgroup analyses with participants who had an excessive HDL (less than 1.15 mmol/L) at baseline.

high-specificity C-reactive protein, in mg/L.

We will conduct a subgroup analyses with participants who had an excessive hsCRP (more than 4 mg/L) at baseline.

Yes/No, must meet at least of the of following criteria on one ovary for "Yes"

1. ≥20 follicles per ovary, measuring 2-9 mm in diameter, OR
2. Ovarian volume >10 mL

Number of cysts measured by ultrasound, in numbers

Size of the largest cyst, measured by ultrasound, in mm

Endometrial thickness, measured with ultrasound, in mm

Normal/abnormal ultrasound, based on the ultrasound report, dichotomous data

length of the menstrual cycle, assessed with a tracking app, in days

Dichotomous data Normal = 21-35 Abnormal: more than 35 days or less than 21 days

Menstruation assessed with a self-reported questionnaire, in days

Average level of menstrual pain on a scale of 0 to 10, 10 being the most severe possible pain. No unit.

Maximal level of pain experienced during menstruation, assessed with a participant-reported questionnaire, on a scale of 0 to 10, 10 being the most severe possible pain. No unit.

Quantity of blood in the menstruation, assessed with a participant-reported questionnaire, on a Lickert scale with 5 options: too scarce, relatively scarce, normal, relatively abundant and too abundant. In points (0 to 4).

Dichotomous Ovulation: A significant increase in BBT of around 0.3°C to 0.6°C observed between the follicular and luteal phases.

No ovulation: no bi-phasic feature.

Left ovary volume in mL.

We will conduct a subgroup analysis with participants who had an abnormal left ovary size (more than 10 mL) at baseline.

Right ovary volume in mL.

We will conduct a subgroup analysis with participants who had an abnormal right ovary size (more than 10 mL) at baseline.

Number of participants who ovulated during their last cycle